أعرض في EDS

702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study

التفاصيل البيبلوغرافية
العنوان:	702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
المؤلفون:	C-K. Tsao, Neeraj Agarwal, Ashok Panneerselvam, Yohann Loriot, Cristina Suarez, Luigi Pagliaro, Toni K. Choueiri, Dominic Curran, Wm. Kevin Kelly, S. Srinivas, Ulka N. Vaishampayan, Bradley Alexander McGregor, Sumanta K. Pal
المصدر:	Annals of Oncology. 31:S554
بيانات النشر:	Elsevier BV, 2020.
سنة النشر:	2020
مصطلحات موضوعية:	chemistry.chemical_compound, Clear cell renal cell carcinoma, First line therapy, Oncology, Cabozantinib, chemistry, business.industry, Atezolizumab, Cancer research, Medicine, Hematology, business, medicine.disease
تدمد:	0923-7534
DOI:	10.1016/j.annonc.2020.08.774
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_________::e24019972903c3357f538ecfcae7ac15 https://doi.org/10.1016/j.annonc.2020.08.774
Rights:	OPEN
رقم الانضمام:	edsair.doi...........e24019972903c3357f538ecfcae7ac15
قاعدة البيانات:	OpenAIRE

الوصف
تدمد:	09237534
DOI:	10.1016/j.annonc.2020.08.774